Metraipolis › archive › dc_138a0aa294ca
Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer… — Europe PMC PMID:42577174
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42577174
- DOI
- 10.3389/fpubh.2026.1843636
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-17T16:21:11.492Z
- SHA-256 of the archived text
1ac208ece979739e69e0f55cf3d5d85e85099222fd37e4bea6ef56cf11c8c34f- Stable URL of this page
https://metraipolis.com/documento/dc_138a0aa294ca
How to cite
Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer… — Europe PMC PMID:42577174 — Europe PMC (en), https://europepmc.org/article/MED/42577174 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_138a0aa294ca (Metraipolis archive dc_138a0aa294ca, sha256 1ac208ece979739e69e0f55cf3d5d85e85099222fd37e4bea6ef56cf11c8c34f)
BibTeX
@misc{dc138a0aa294ca,
title = {Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer… — Europe PMC PMID:42577174},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42577174},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_138a0aa294ca; sha256 1ac208ece979739e69e0f55cf3d5d85e85099222fd37e4bea6ef56cf11c8c34f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42577174. Agents can read the archived copy with the MCP tool read_document.